Top Page
Genor Biopharma Holdings Limited
(6998)
Genor Biopharma Holdings Limited (6998) vs. iShares MSCI Hong Kong ETF (EWH)
Genor Biopharma Holdings Limited Business Overview & Revenue Model
Genor Biopharma Holdings Limited Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 224.00M | 206.23M | 0.00 | 15.93M | 0.00 | 10.33M |
| Gross Profit | 223.01M | 204.89M | 0.00 | 14.95M | 0.00 | 7.74M |
| EBITDA | 10.07M | -5.15M | -551.01M | -675.89M | -840.19M | -2.98B |
| Net Income | 20.15M | -51.28M | -674.36M | -730.40M | -865.37M | -3.03B |
Balance Sheet | ||||||
| Total Assets | 1.32B | 1.29B | 1.45B | 2.12B | 2.86B | 3.57B |
| Cash, Cash Equivalents and Short-Term Investments | 1.01B | 1.06B | 1.17B | 1.59B | 2.20B | 2.93B |
| Total Debt | 745.00K | 911.00K | 7.16M | 28.59M | 57.41M | 31.06M |
| Total Liabilities | 226.09M | 138.05M | 256.18M | 309.87M | 369.73M | 336.32M |
| Stockholders Equity | 1.10B | 1.15B | 1.19B | 1.80B | 2.49B | 3.23B |
Cash Flow | ||||||
| Free Cash Flow | -32.86M | -123.55M | -426.15M | -590.56M | -695.13M | -885.01M |
| Operating Cash Flow | -32.37M | -121.98M | -425.12M | -577.61M | -623.74M | -786.72M |
| Investing Cash Flow | -295.42M | 8.01M | 5.99M | -12.94M | -54.26M | -98.24M |
| Financing Cash Flow | 540.50K | -1.56M | -6.82M | -57.39M | 17.57M | 3.74B |
Genor Biopharma Holdings Limited Technical Analysis
Genor Biopharma Holdings Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | HK$3.18B | 392.38 | 0.99% | ― | 9.41% | -32.69% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$5.02B | 56.31 | 2.04% | ― | 1447.56% | ― | |
47 Neutral | HK$2.02B | -6.68 | -14.84% | ― | -38.38% | -22.12% | |
44 Neutral | HK$1.28B | -13.25 | -14.87% | ― | ― | 22.65% | |
43 Neutral | HK$1.60B | -6.01 | ― | ― | ― | 27.90% | |
41 Neutral | HK$1.01B | -1.48 | -51.56% | ― | 2.45% | 2.58% |
Genor Biopharma Holdings Limited Corporate Events
Edding Genor Group Holdings Limited has announced that its board intends to conduct on-market share repurchases from time to time under a general mandate granted by shareholders at the company’s 26 June 2025 annual general meeting. The repurchased shares may be cancelled, held in treasury, sold or transferred as the company deems appropriate, with the board stating that this capital management move is in the interests of the company and its shareholders, though it emphasized that any buybacks will depend on market conditions and regulatory compliance and provided no assurance on timing, volume or pricing, urging investors to exercise caution when dealing in its securities.
The most recent analyst rating on (HK:6998) stock is a Hold with a HK$2.50 price target. To see the full list of analyst forecasts on Genor Biopharma Holdings Limited stock, see the HK:6998 Stock Forecast page.
Edding Genor Group Holdings Limited has announced the current composition of its board of directors, listing executive, non-executive and independent non-executive directors, including Ni Xin and Zhai Jing as executive directors. The company also disclosed the membership and chairmanship roles across its three key board committees—audit, compensation and nomination—clarifying oversight responsibilities and governance structure, which may enhance transparency and strengthen corporate governance for shareholders and other stakeholders.
Edding Genor Group Holdings Limited has completed a very substantial acquisition via a merger between its merger subsidiary and the target company, with the transaction structured as a reverse takeover and satisfied through the issue of approximately 1.48 billion consideration shares under a specific mandate. The merger’s effective completion on 30 December 2025 follows shareholder approval and listing consent for the new shares, and is accompanied by a broad corporate overhaul including a new company name, logo and website, adoption of a one-off share option plan, removal of the stock marker, and changes to the board, board committees, authorised representatives, joint company secretaries and principal place of business in Hong Kong, signalling a significant repositioning of the group’s capital structure and governance for its next phase of development.
Genor Biopharma announced that the Hong Kong Stock Exchange has conditionally approved the dis-application of specific biotech listing rules to the company, effective upon completion of its proposed merger, after confirming that the enlarged group will meet the market capitalization and revenue thresholds under the main board’s standard Rule 8.05(3). Once the merger closes, the company’s shares will no longer carry the “-B” marker that denotes pre-revenue biotech issuers, its stock short name will change accordingly while the stock code remains 6998, and existing share certificates will remain valid, underscoring Genor’s transition from a Chapter 18A biotech issuer to a fully qualifying main board company with enhanced scale and financial profile.
Genor Biopharma Holdings Limited announced that all resolutions proposed at its extraordinary general meeting on 22 December 2025 were duly passed by poll, including approval of a merger agreement dated 13 September 2024 with a target company and the related issuance of consideration shares under a specific mandate. Shareholders also approved the grant of a whitewash waiver, consent to a special deal and an increase in the company’s authorised share capital, measures that collectively facilitate the proposed merger and potential new listing, and position the company for larger-scale equity financing and strategic expansion, with directors authorised to execute all necessary documents and actions to implement these transactions.
Genor Biopharma Holdings Limited announced the inclusion of its drug Lerociclib (GB491) in China’s National Reimbursement Drug List, effective January 2026. This inclusion is expected to enhance patient access, reduce financial burdens, and accelerate the drug’s commercialization and market penetration, thereby increasing returns for innovation.
Genor Biopharma Holdings Limited, a company incorporated in the Cayman Islands, announced the closure of its register of members in preparation for an extraordinary general meeting (EGM) scheduled for December 22, 2025. The closure will occur from December 18 to December 22, during which no share transfers will be registered. This meeting is significant for shareholders as it determines their eligibility to attend and vote, impacting their engagement and influence in company decisions.
Genor Biopharma Holdings Limited has announced a series of significant corporate actions, including a proposed merger, a reverse takeover, and an increase in authorized share capital. These moves are part of a strategic effort to enhance the company’s market positioning and operational capabilities. The proposed merger involves issuing consideration shares under a specific mandate, and the company is applying for a whitewash waiver to facilitate this process. Additionally, a special deal related to a retention plan for shareholder personnel and a proposed change of company name are part of the comprehensive strategy. The company has also planned the adoption of a one-off share option plan to incentivize key personnel. These initiatives are subject to shareholder approval and regulatory conditions, with potential implications for the company’s future growth and stakeholder interests.
Genor Biopharma Holdings Limited has announced an Extraordinary General Meeting to be held on December 22, 2025, to discuss and potentially approve a proposed merger and a retention plan. The merger involves a specific mandate to issue shares to target shareholders, while the retention plan requires approval under the Takeovers Code. These resolutions, if passed, could significantly impact the company’s strategic direction and shareholder value.
Genor Biopharma Holdings Limited has announced a series of significant corporate actions, including a proposed merger and a reverse takeover, which involve the issuance of consideration shares and a new listing application. The company is also seeking a whitewash waiver and plans to increase its authorized share capital and adopt a one-off share option plan. The dispatch of the circular related to these transactions has been delayed, with the company working closely with regulators to address comments and finalize the information. The proposed merger and associated actions are subject to various conditions and approvals, and shareholders are advised to exercise caution.